Objective:To explore the prognostic value of long non-coding RNA (lncRNA) AL445524.1 in hepatocellular carcinoma (HCC) and its regulatory effect on liver cancer cells.Methods:Based on the TCGA database, bioinformatics analysis was conducted to assess the expression levels of AL445524.1 in HCC. Using the median expression level of AL445524.1 as the cut-off value, 343 HCC patients were divided into high expression group and low expression group. Survival analysis was performed using Kaplan-Meier curves. Univariate and multivariate Cox proportional hazards regression models were employed to analyze the relationship between AL445524.1 expression, other clinical characteristics, and patients' prognosis, identifying independent risk factors for the prognosis of HCC patients. Based on the results of the multivariate analysis, patients with complete data were randomly divided into a testing set ( n=215) and a training set ( n=92) in a 7∶3 ratio using a random number table method, and a nomogram prognostic prediction model for HCC was constructed. Receiver operator characteristic (ROC) curves were plotted to calculate the area under the curve (AUC) to analyze and validate the predictive performance of the model. Functional enrichment analysis was conducted on the differentially expressed genes regulated by AL445524.1. The expression level of AL445524.1 in liver cancer cells was detected using RT-PCR. Human hepatoma cell lines HCCLM3 were divided into si-AL445524.1-1, si-AL445524.1-2, si-AL445524.1-3 and si-NC groups. The CCK-8 assay was used to assess cell proliferation capability; cell scratch and Transwell assays were performed to evaluate cell migration and invasion abilities; and flow cytometry was utilized to detect cell apoptosis. Results:The expression of AL445524.1 in liver cancer tissues was significantly higher than that in para-carcinoma tissues (4.38±1.26 vs. 2.08±0.45, t=24.58, P<0.001). Kaplan-Meier survival analysis showed that the 5-year overall survival (OS) rate for HCC patients in high AL445524.1 expression group ( n=170) was 37.37%, and that of patients in low AL445524.1 expression group ( n=173) was 58.38%, with a statistically significant difference ( χ2=8.83, P=0.003). Multivariate analysis showed that tumor recurrence ( HR=2.58, 95% CI: 1.64-4.07, P<0.001), clinical stage ( HR=2.49, 95% CI: 1.63-3.81, P<0.001), and AL445524.1 expression ( HR=1.23, 95% CI: 1.06-1.41, P=0.010) were independent factors affecting the prognosis of HCC patients. A nomogram prognostic prediction model was constructed based on tumor recurrence, clinical stage, and AL445524.1 expression, with the model risk score calculated as: risk score=0.774×tumor recurrence+0.753×clinical stage+0.231×AL445524.1. The prediction model C-index values of 0.726, 0.660, and 0.678 in the training set, testing set, and overall set, respectively. ROC curve analysis showed that the AUC values for the 1-year OS rates in the training set, testing set, and overall set were 0.746, 0.630, and 0.684, respectively; the AUC values for the 3-year OS rates were 0.778, 0.736, and 0.743; and the AUC values for the 5-year OS rates were 0.794, 0.760, and 0.774. In the training set, the test set and the overall set, the predictive performance of the model score in predicting the 5-year OS rate of patients was superior to the individual predictions of AL445524.1 expression, clinical stage and tumor recurrence alone (all P<0.05). The 5-year overall survival (OS) rates of high-risk group ( n=154) and low-risk group ( n=153) were 33.54% and 77.73%, respectively, with a statistically significant difference ( χ2=28.97, P<0.001). GO and KEGG enrichment analysis suggested that the differential expression of AL445524.1 genes in high and low expression groups was mainly related to lipid metabolism and oxidation. GSEA analysis showed that the oxidative phosphorylation pathway was significantly enriched in HCC patients with high expression of AL445524.1. In vitro experiments showed that AL445524.1 expression was higher in liver cancer cells (1.97±0.14) compared to normal liver cells (1.00±0.10), with a statistically significant difference ( t=11.62, P=0.007). Silencing AL445524.1 could significantly inhibit the proliferation, migration, and invasion of liver cancer cells and promote apoptosis. In the CCK-8 proliferation experiment, the A450 values of the si-NC, si-AL445524.1-1, si-AL445524.1-2, and si-AL445524.1-3 groups after 24 hours were 0.433±0.012, 0.377±0.020, 0.383±0.020, and 0.423±0.005, respectively, with a statistically significant difference ( F=20.51, P<0.001). Additionally, the cell proliferation in the si-AL445524.1-1, si-AL445524.1-2, and si-AL445524.1-3 groups was lower than that in the si-NC group (all P<0.001). The cell scratch assay showed that the scratch healing rates of the above 4 groups were 33.60%±6.15%, 21.60%±4.30%, 26.40%± 4.60%, and 27.30%±2.60%, respectively, with a statistically significant difference ( F=42.71, P<0.001). The scratch healing rates of the si-AL445524.1-1, si-AL445524.1-2, and si-AL445524.1-3 groups were also significantly lower than that of the si-NC group (all P<0.001). Transwell migration and invasion experiments revealed that the number of migrated cells in the above 4 groups were 293.50±14.80, 110.50±10.28, 132.44±5.57, and 115.25±8.66, respectively, with a statistically significant difference ( F=374.16, P<0.001). The number of migrated cells in the si-AL445524.1-1, si-AL445524.1-2, and si-AL445524.1-3 groups were significantly lower than that in the si-NC group (all P<0.001). For the invasion assay, the number of invaded cells in the above 4 groups were 247.00±9.49, 119.00±5.57, 153.25±5.85, and 163.67±5.51, respectively, with a statistically significant difference ( F=218.14, P<0.001). The number of invaded cells in the si-AL445524.1-1, si-AL445524.1-2, and si-AL445524.1-3 groups were also significantly lower than that in the si-NC group (all P<0.001). Flow cytometry showed that the apoptosis rates of the above 4 groups were 1.70%±0.08%, 2.17%±0.11%, 2.38%±0.08%, and 2.02%±0.27%, respectively, with a statistically significant difference ( F=29.36, P<0.001). The apoptosis rate in the si-AL445524.1-1, si-AL445524.1-2, and si-AL445524.1-3 groups were significantly higher than that in the si-NC group (all P<0.001) . Conclusion:AL445524.1 can serve as a prognostic marker for HCC. The AL445524.1-related prognostic prediction model demonstrates high accuracy in predicting the 5-year OS rate of HCC patients. Patients with high AL445524.1 expression have poorer survival prognosis. Silencing AL445524.1 can inhibit liver cancer cell proliferation, migration, and invasion while promoting apoptosis, which may be related to cellular lipid metabolism or oxidative phosphorylation.

ObjectiveWearing protective masks for a long time causes a large number of frontline health care workers to suffer different degrees of pressure injury or facial skin rupture in response to COVID-19. This paper aims to analyze the occurrence characteristics and related factors of pressure injury related to devices, and provide the basis for taking countermeasures. Methods There was online investigation of skin injuries caused by wearing protective equipment in medical staff. Descriptive analysis was carried out on the occurrence characteristics of pressure-induced injury, and influencing factors were analyzed through logistic regression model. ResultsThere were a total of 2901 valid questionnaires. The results showed that the incidence of pressure injury caused by protective equipment was 26.34%, mainly in the bridge of the nose (20.41%), cheek (20.23%), auricle (17.82%) and forehead (8.86%). Multivariate Logistic regression model analysis showed that the major associated factors, which presented increasing risk, were sweating and dampness (OR=12.72, 95%CI 8.36-17.30), wearing level-3 protective equipment (OR=3.55, 95%CI 2.47-5.08), wearing level-2 protective equipment (OR=3.37, 95%CI 2.47-4.60), wearing time (OR=1.29, 95%CI 1.05~1.58) and occupation (OR=1.57, 95%CI 1.00~2.49). Conclusion There is the high incidence of pressure injuries to health care workers caused by protective equipment against COVID-19. The main risk factors for facial stress injury of medical staff are sweating and dampness, wearing level-3 and level-2 protective equipment and wearing time.

Objective To observe Shenci capsule's effect on immunologic function and hematological tox-icity of patients with advanced non-small cell lung cancer.Methods 60 cases of patients with advanced non-small cell lung cancer were chosen and divided into the therapy group and the control group randomly with 30 cases in each group respectively. While patients in the control group were administered simple GP chemotherapy regime, patients in the therapy group were administered Shenci capsule treatment orally in addition to the therapy in the control group.Comparisons were made of the variations in the subgroup of T lymphocyte(including the absolute val-ue of CD3+cell,the absolute value of CD4+cell,the absolute value of CD8+cell and CD4+/CD8+ratio)of hematology before and after chemotherapy between the two groups of patients. Results No significant discrepancy was found in the comparison of the absolute value of CD3+cell,the absolute value of CD4+cell,the absolute value of CD8+cell and CD4+/CD8+ratio before the chemotherapy between the two groups(P > 0.05)and the absolute value of CD3+cell,and the absolute value of CD4+cell of both groups decreased significantly after the chemotherapy(P<0.05), especially in the control group(P < 0.05). The hematological toxicity of the therapy group was lower than that in the control group(P < 0.05)after the chemotherapy. Conclusion Shenci capsule was capable of enhancing the body immunity in advanced non-small cell lung cancer and alleviating hematological toxicity.

There has been an ongoing search for clinically acceptable methods for the accurate, efficient and simple diagnosis and prognosis of hepatocellular carcinoma (HCC). Optical spectroscopy is a technique with potential clinical applications to diagnose cancer diseases. The purpose of this study was to obtain the optical properties of HCC tissues and non-tumorous hepatic tissues and identify the difference between them. A total of 55 tissue samples (HCC tissue, n=38; non-tumorous hepatic tissue, n=17) were surgically resected from patients with HCC. The optical parameters were measured in 10-nm steps using single-integrating-sphere system in the wavelength range of 400 to 1800 nm. It was found that the optical properties and their differences varied with the wavelength for the HCC tissue and the non-tumorous hepatic tissue in the entire wavelength range of research. The absorption coefficient of the HCC tissue (1.48±0.99, 1.46±0.88, 0.86±0.61, 2.15±0.53, 0.54±0.10, 0.79±0.15 mm(-1)) was significantly lower than that of the non-tumorous hepatic tissue (2.79±1.73, 3.13±1.47, 3.06±2.79, 2.57±0.55, 0.62±0.10, 0.93±0.16 mm(-1)) at wavelengths of 400, 410, 450, 1450, 1660 and 1800 nm, respectively (P<0.05). The reduced scattering coefficient of HCC tissue (5.28±1.70, 4.91±1.54, 1.26±0.35 mm(-1)) and non-tumorous hepatic tissue (8.14±3.70, 9.27±3.08, 2.55±0.57 mm(-1)) was significantly different at 460, 500 and 1800 nm respectively (P<0.05). These results show different pathologic liver tissues have different optical properties. It provides a better understanding of the relationship between optical parameters and physiological characteristics in human liver tissues. And it would be very useful for developing a non-invasive, real-time, simple and efficient way for medical management of HCC in the future.

There has been an ongoing search for clinically acceptable methods for the accurate,efficient and simple diagnosis and prognosis of hepatocellular carcinoma (HCC).Optical spectroscopy is a technique with potential clinical applications to diagnose cancer diseases.The purpose of this study was to obtain the optical properties of HCC tissues and non-tumorous hepatic tissues and identify the difference between them.A total of 55 tissue samples (HCC tissue,n=38; non-tumorous hepatic tissue,n=17)were surgically resected from patients with HCC.The optical parameters were measured in 10-nm steps using single-integrating-sphere system in the wavelength range of 400 to 1800 nm.It was found that the optical properties and their differences varied with the wavelength for the HCC tissue and the non-tumorous hepatic tissue in the entire wavelength range of research.The absorption coefficient of the HCC tissue (1.48±0.99,1.46±0.88,0.86±0.61,2.15±0.53,0.54±0.10,0.79±0.15 mm-1) was significantly lower than that of the non-tumorous hepatic tissue (2.79±1.73,3.13±1.47,3.06±2.79,2.57±0.55,0.62±0.10,0.93±0.16 mm-1) at wavelengths of 400,410,450,1450,1660 and 1800 nm,respectively (P＜0.05).The reduced scattering coefficient of HCC tissue (5.28±1.70,4.91±1.54,1.26±0.35 mm-1) and non-tumorous hepatic tissue (8.14±3.70,9.27±3.08,2.55±0.57 mm-1) was significantly different at 460,500 and 1800 nm respectively (P＜0.05).These results show different pathologic liver tissues have different optical properties.It provides a better understanding of the relationship between optical parameters and physiological characteristics in human liver tissues.And it would be very useful for developing a non-invasive,real-time,simple and efficient way for medical management of HCC in the future.

Objective To detect the expression of survivin mRNA in cervical cancer cell lines using molecular beacon imaging technology. Methods Human cervical cancer cells (HeLa and SiHa) and human fetal lung fibroblast HFL-I were cultured in vitro. After adding 100 nmol/L survivin mRNA molecular beacon, the fluorescent signals were observed under fluorescent microscope. The expressions of survivin in cervical cancer cells and HFL-I cell were examined by immunocytochemical streptravidin-biothin peroxidase (SP) assay at the same time. Results Two kinds of survivin mRNA molecular beacon, with different color fluorescence, had strong fluorescent signal in cervical cancer cell lines, and the signal in SiHa cell line was stronger, but these signals were not found in HFL-I ; Immunocytochemical staining of positive survivin was located in the cytoplasm of cervical cancer cell lines HeLa and SiHa, whereas, no expression of survivin was detected in HFL-I cell line. Conclusion The technology of molecular beacon imaging can be used to detect the expression of survivin mRNA in viable cells successfully, and may provide a new approach to the diagnosis of early stage cervical cancer and the following-up in the clinic.